Jump Financial LLC Invests $579,000 in OrthoPediatrics Corp. (NASDAQ:KIDS)

Jump Financial LLC acquired a new stake in OrthoPediatrics Corp. (NASDAQ:KIDSFree Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 17,800 shares of the company’s stock, valued at approximately $579,000. Jump Financial LLC owned 0.08% of OrthoPediatrics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in KIDS. Prime Capital Investment Advisors LLC acquired a new position in OrthoPediatrics in the fourth quarter valued at approximately $2,035,000. Vanguard Group Inc. raised its holdings in shares of OrthoPediatrics by 1.3% during the third quarter. Vanguard Group Inc. now owns 860,804 shares of the company’s stock valued at $27,546,000 after purchasing an additional 10,861 shares during the period. Blue Trust Inc. boosted its position in shares of OrthoPediatrics by 1.5% during the 4th quarter. Blue Trust Inc. now owns 28,670 shares of the company’s stock worth $917,000 after purchasing an additional 421 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of OrthoPediatrics by 0.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,731 shares of the company’s stock valued at $3,895,000 after buying an additional 549 shares during the period. Finally, Conestoga Capital Advisors LLC increased its position in OrthoPediatrics by 24.0% in the 4th quarter. Conestoga Capital Advisors LLC now owns 45,353 shares of the company’s stock valued at $1,474,000 after buying an additional 8,770 shares in the last quarter. Institutional investors own 69.05% of the company’s stock.

Insider Activity at OrthoPediatrics

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 2,741 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $75,624.19. Following the completion of the transaction, the general counsel now owns 52,403 shares in the company, valued at approximately $1,445,798.77. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Fred Hite sold 3,195 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $88,150.05. Following the transaction, the chief financial officer now owns 94,072 shares in the company, valued at $2,595,446.48. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Daniel J. Gerritzen sold 2,741 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $75,624.19. Following the completion of the sale, the general counsel now directly owns 52,403 shares of the company’s stock, valued at $1,445,798.77. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,253 shares of company stock valued at $477,375. 31.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on KIDS. Truist Financial raised their price objective on OrthoPediatrics from $35.00 to $38.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. JMP Securities restated a “market outperform” rating and set a $50.00 price objective on shares of OrthoPediatrics in a report on Tuesday, May 7th. Finally, Needham & Company LLC lifted their price objective on shares of OrthoPediatrics from $37.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, May 7th.

View Our Latest Report on OrthoPediatrics

OrthoPediatrics Trading Up 1.3 %

NASDAQ KIDS opened at $32.96 on Wednesday. The company has a current ratio of 4.45, a quick ratio of 1.99 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $29.68 and a 200 day simple moving average of $29.57. OrthoPediatrics Corp. has a 12 month low of $23.10 and a 12 month high of $48.47. The firm has a market capitalization of $785.44 million, a P/E ratio of -34.33 and a beta of 1.16.

OrthoPediatrics (NASDAQ:KIDSGet Free Report) last announced its earnings results on Wednesday, March 6th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. OrthoPediatrics had a negative net margin of 13.58% and a negative return on equity of 5.12%. The company had revenue of $37.61 million during the quarter, compared to the consensus estimate of $37.59 million. On average, analysts predict that OrthoPediatrics Corp. will post -1.2 EPS for the current fiscal year.

About OrthoPediatrics

(Free Report)

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

See Also

Want to see what other hedge funds are holding KIDS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OrthoPediatrics Corp. (NASDAQ:KIDSFree Report).

Institutional Ownership by Quarter for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.